Johnson & Johnson MedTech Archives - Page 7 of 7

Depuy Synthes wins FDA clearance for Teligen system

Johnson & Johnson MedTech’s DePuy Synthes this week announced it received FDA 510(k) clearance for its Teligen technology platform for spinal procedures.

Teligen is an integrated technology platform that enables minimally invasive surgical transforaminal lumber interbody fusion (MIS-TLIF) procedures using digital tools for visualization and access. The system has a tower with a camera control system, a VueLIF-T procedure kit with a disposable HD camera, a Teligen clear discectomy device and patient-based disposable ports.

DePuy Synthes’ new system integrates the company’s Unleash bundle of implant solutions that streamline the main stages in MIS-TLIF.

TLIF is a common posterior surgical approach used for treating patients with persistent pain in their lower backs and have spinal instability and fail to respond to noninvasive management. According to the company, TLIF can present clinical challenges like greater soft tissue disruptio…

Johnson & Johnson beats The Street in Q3, MedTech sales rise

Johnson & Johnson (NYSE:JNJ) today reported third-quarter results that topped the consensus forecast, with MedTech business sales up more than 2%.

The New Brunswick, New Jersey-based company posted profits of $4.5 billion, or $1.68 per share in the quarter. It pulled in sales of $23.8 billion for the three months ended Sept. 30, 2022. That marked a 21.6% bottom-line gain on sales growth of 1.9%.

Adjusted to exclude one-time items, earnings per share were $2.48. That beat Wall Street expectations by 7¢, while analysts looked for sales of $23.3 billion.

J&J’s MedTech arm also saw rises during the quarter. It posted sales of nearly $6.8 billion for a 2.1% improvement over this time last year. The company attributed the performance to drivers such as electrophysiology products, contact lenses, orthopedic trauma therapies and wound closure products.

Its Pharmaceutical business performed the best with revenues of $13.2 million (up 2.6% on …

The 10 largest medtech employers — and what their employees really think

Employees of the 10 largest medtech employers are happy to be a part of a company that is having a positive impact on patient populations.

That was one major takeaway as MassDevice compiled some current and former employee reviews posted on Glassdoor.

Medtronic, Philips and Johnson & Johnson MedTech top the list of largest medtech employers. The 10 companies we looked at were the largest employers in Medical Design & Outsourcing‘s newest Big 100 report on the largest medical device companies.

Company Employees Medtronic 95,000 Philips 78,189 Johnson & Johnson MedTech 75,000

As with most companies, there are some qualms with corporate bureaucracy and reorganizations creating frustration for employees.

Employment in the medtech industry is on the rise, according to a recent analysis of our Medtech Big 100 data. There were 1,268,924 employees among the 100 largest companies that report human capital in their annual repor…

What are the largest medical device companies?

Medtronic, Johnson & Johnson MedTech and Siemens Healthineers top the Big 100 list of largest medical device companies by revenue.

The 2022 edition of MassDevice and Medical Design & Outsourcing‘s Big 100 report also holds surprises. Big conglomerates are spinning out medtech businesses as stand-alone companies, and that means changes to the list of 100 largest medical device companies.

Colfax, for example, engaged in business moves that turned DJO’s parent into Enovis, a large, stand-alone orthopedic device company that is No. 56 in 2022’s Big 100. ZimVie, formerly Zimmer Biomet’s spine and dental business, is 69th. And after decades under larger corporate umbrellas, Cordis debuts at No. 76 on the list.

We collected thousands of data points to size up the industry’s publicly traded companies and privately held firms. The Big 100 includes annual revenue, R&D spending, employee counts, key leaders, headquarters locatio…

How an Embotrap stent retriever thrombectomy treats ischemic strokes

Michael Gilvarry is the GM of Cerenovus in Galway, Ireland. [Photo courtesy of Johnson & Johnson MedTech]Gilvarry is the GM of Cerenovus in Galway, Ireland. [Photo courtesy of Johnson & Johnson Medtech]

To catch a clot, you must first understand a clot, and Michael Gilvarry has spent years doing just that.

Gilvarry is the GM of Cerenovus in Galway, Ireland. He founded the Johnson & Johnson Medtech unit’s stroke science research arm and leads the acute ischemic stroke R&D portfolio.

That research led to the development and design of the Embotrap stent retriever device for thrombectomies, which helps stroke patients by removing the clots blocking the flow of blood to their brains.

“How the device design is informed by stroke science is something that we feel is really unique about the device,” he said in an interview. “All of that work we’ve done has le…

The biggest medtech personnel moves so far in 2022

In the ever-changing world of medtech, those who are leading the companies are bound to move around a bit.

At the end of last year, we compiled a list of medtech’s biggest personnel changes in 2021. Throughout just over half of 2022, we’ve already seen a slew of major moves around some of the space’s most powerful players.

Here is a list of some of the biggest personnel changes in medtech so far in 2022:

3M’s healthcare president retires 3M Health Care Business Group President Mojdeh Poul [Image courtesy of 3M]Mojdeh Poul, the president of 3M’s healthcare business, announced in May that she would retire from the position and her retirement was made effective on July 1.

Poul joined 3M in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M divisions, including infection prevention, 3M Canada, and sa…

J&J focuses on strengthening MedTech business, dampens M&A talk

Johnson & Johnson (NYSE:JNJ) CEO Joaquin Duato says the company isn’t harping on mergers and acquisitions as it grows its MedTech business.

Speaking on the company’s second-quarter earnings call, Duato emphasized that Johnson & Johnson MedTech, its rebranded medical devices business, has its sights set on strengthening current strongholds and accessing high-growth market segments to accelerate its own growth.

“When it comes to MedTech, the focus continues to be strengthening our current strongholds and also accessing some high-growth market segments to accelerate growth,” Duato said on the call, as transcribed by The Motley Fool. “And the target areas are the ones that we are operating today: high health orthopedics, cardiology, surgery, historically, it’s been a predictor of our success to the extent we were closer to the areas that we have capabilities.”

Johnson & Johnson MedTech saw a 1.1% decrease…

Johnson & Johnson beats The Street in Q2, lowers full-year guidance

Johnson & Johnson (NYSE:JNJ) shares were up before hours on second-quarter results that came in ahead of the consensus forecast.

The New Brunswick, New Jersey-based company posted profits of $4.8 billion, or $1.80 per share, on sales of $24 billion for the quarter ended June 2022, for a 23.3% bottom-line slide on sales growth of 3%.

Adjusted to exclude one-time items, earnings per share were $2.59, 2¢ ahead of Wall Street, where analysts were looking for sales of $23.8 billion.

Johnson & Johnson MedTech, formerly the company’s medical devices segment, experienced a 1.1% decrease in sales, pulling in nearly $6.9 billion in revenues for the three-month period. The company’s adjusted operational sales grew 3.4%, driven primarily by contact lenses and surgical vision products, as well as electrophysiology products, according to a news release.

Growth in the MedTech segment was “partially offset” by COVID-19-related mobi…

Johnson & Johnson MedTech appoints new CFO

Johnson & Johnson MedTech (NYSE:JNJ) announced that Kurt Van den Bosch has been appointed as its CFO, group finance.

Van den Bosch will be a member of Johnson & Johnson’s global finance team, reporting to the company’s EVP and CFO Joe Wolk. Van den Bosch’s role includes providing financial leadership to the global Johnson & Johnson MedTech organization.

He most recently served as area VP of mid-sized markets for J&J MedTech EMEA, overseeing the EMEA business that included the markets of Austria, Belgium, Greece, Israel, Portugal, Switzerland, the Netherlands and Scandinavian countries.

Van den Bosch joined Johnson & Johnson’s Janssen Pharmaceuticals, Belgium, company in 1990 as part of its finance team and has held a range of roles with increasing responsibility since. Before joining J&J MedTech, he was CFO for Janssen EMEA from 2012 to 2014, before being appointed to the role of CFO for global surgery EMEA…

DePuy Synthes adds two knee systems to Attune Knee portfolio

Attune Cementless Fixed Bearing knee and Attune Medial Stabilized knee [Images courtesy of DePuy Synthes]Johnson & Johnson MedTech announced that its orthopedics company DePuy Synthes has added Cementless Fixed Bearing knee and Medial Stabilized knee to its Attune Knee portfolio.

The company’s two new innovations build on Attune’s kinematic features that include Gradius Curve and Glideright Articulation. Both knee additions work seamlessly with DePuy Synthes’ Velys robotic-assisted surgical system.

“Through our DePuy Synthes knee solutions, we’re revolutionizing the traditional approach to total knee arthroplasty by offering patients a tailored surgical experience based on the combination of our kinematically advanced implants, our differentiated digital technology, and patient-specific techniques,” Juston Gates, worldwide VP of knee reconstruction for DePuy Synthes, said in a news release. “We believe that this combin…

Johnson & Johnson Medical Devices drops ‘medical devices’ in rebranding

Johnson & Johnson Medical Devices has rebranded as Johnson & Johnson MedTech as the unit moves deeper into digital technology.

New Brunswick, New Jersey-based Johnson & Johnson (NYSE: JNJ) noted the coming change in its 2022 annual report published last month, saying the switch would take effect in the company’s first fiscal quarter.

Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy [Photo courtesy of Johnson & Johnson]That preview was followed by an announcement of approximately 100 words, mostly attributed to Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy.

Johnson & Johnson provided more information to Medical Design & Outsourcing today.

Get the full story at our sister site, Medical Design & Outsourcing.

Johnson & Johnson Medical Devices drops ‘medical devices’ in rebranding

Johnson & Johnson Medical Devices has rebranded as Johnson & Johnson MedTech as the unit moves deeper into digital technology.

New Brunswick, New Jersey-based Johnson & Johnson (NYSE: JNJ) noted the coming change in its 2022 annual report published last month, saying the switch would take effect in the company’s first fiscal quarter.

That preview was followed by a March 7 announcement of approximately 100 words, mostly attributed to Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy.

Johnson & Johnson MedTech EVP and Executive Chair Ashley McEvoy [Photo courtesy of Johnson & Johnson]

“Our business sits at the compelling intersection of medical devices and medical technology, and as the world’s most broadly based medtech company, we are committed to delivering breakthrough scientific innovation and reimagining health in an increasingly digital world,”…